Author: kodiac

  • Polygalasaponin F

    Oleanane-type triterpenoid saponin with multi-target neuroprotective, anti-inflammatory, and cognition-enhancing activity

    An oleanane triterpenoid saponin isolated from Polygala japonica Houtt. with demonstrated neuroprotection against ischemic and excitotoxic injury, long-term potentiation enhancement via NMDA receptor activation, and anti-neuroinflammatory activity through TLR4-PI3K/AKT-NF-kB and TXNIP/NLRP3 pathway modulation.

    Abstract

    Polygalasaponin F (PGSF) is an oleanane-type triterpenoid saponin originally isolated from the aerial parts of Polygala japonica Houtt., a perennial herb of the Polygalaceae family used in traditional East Asian medicine for its sedative, expectorant, and cognition-enhancing properties. The compound has a molecular formula of C53H86O23 (molecular weight 1091.2 g/mol) and bears a presqualene-derived oleanane aglycone substituted with a 3-O-beta-D-glucopyranosyl unit and a C-28 ester-linked trisaccharide chain composed of glucopyranose, rhamnopyranose, and xylopyranose residues. PGSF has emerged as a compound of substantial preclinical research interest across multiple neuroprotective and anti-inflammatory domains, supported by a growing body of in vitro and in vivo evidence published principally between 2012 and 2025.

    The pharmacological profile of PGSF is characterized by multi-target activity converging on neuronal survival, synaptic plasticity, and neuroinflammatory suppression. In adult rat hippocampal slices, PGSF at 1 to 10 micromolar induces sustained long-term potentiation (LTP) in the dentate gyrus through activation of N-methyl-D-aspartate receptors (NMDARs), with downstream phosphorylation of NR2B, calcium/calmodulin-dependent protein kinase II (CaMKII), extracellular signal-regulated kinase (ERK), and cyclic AMP response element-binding protein (CREB), placing it among a small number of natural saponins with direct electrophysiological evidence of synaptic strengthening. In cultured hippocampal neurons exposed to glutamate excitotoxicity, PGSF produces concentration-dependent neuroprotection by attenuating cytosolic calcium overload and modulating NMDAR subunit expression, specifically preserving NR2A while limiting excess NR2B-mediated calcium influx. In oxygen-glucose deprivation and reoxygenation (OGD/R) models of ischemic injury using PC12 cells and primary cortical neurons, PGSF activates the PI3K/Akt survival signaling pathway, upregulates the Bcl-2/Bax ratio, and suppresses caspase-3 activation to inhibit apoptosis.

    The anti-inflammatory pharmacology of PGSF operates through at least two characterized signaling cascades. In lipopolysaccharide-stimulated BV-2 microglial cells, PGSF suppresses tumor necrosis factor alpha (TNF-alpha) release through inhibition of the toll-like receptor 4 (TLR4) to phosphoinositide 3-kinase (PI3K) to protein kinase B (AKT) to nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling axis. In middle cerebral artery occlusion (MCAO) rat models of focal ischemia and reperfusion, PGSF ameliorates neurological deficit, reduces infarct volume, and inhibits the thioredoxin-interacting protein (TXNIP) to NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome signaling pathway. More recent studies (2024 to 2025) have identified additional mechanistic targets: PGSF downregulates the Na-K-2Cl cotransporter 1 (NKCC1) through enhanced DNA methylation, thereby reducing blood-brain barrier disruption and cerebral edema following ischemia-reperfusion, and PGSF alleviates cerebral ischemia-reperfusion injury through inhibition of excessive mitophagy, preserving mitochondrial membrane potential and reducing mitochondrial reactive oxygen species accumulation.

    No clinical trials of PGSF in humans have been conducted. The compound remains in the preclinical investigational phase, with the entirety of the evidence base derived from in vitro cell culture systems and rodent models of cerebral ischemia, glutamate excitotoxicity, and neuroinflammation. Pharmacokinetic data specific to PGSF in any species are not available in published form; general considerations for triterpenoid saponin bioavailability (gastrointestinal hydrolysis of glycosidic bonds, limited oral absorption of intact saponin, hepatic first-pass metabolism) apply and represent a translational barrier that has not been formally addressed. The compound is available from multiple research chemical suppliers at greater than 95 percent purity for in vitro and in vivo research applications. This monograph reviews the chemistry, isolation, and structural characterization of PGSF; the multi-target molecular pharmacology across NMDA receptor, PI3K/Akt, TLR4/NF-kB, TXNIP/NLRP3, NKCC1, and mitophagy pathways; the preclinical evidence base in ischemic stroke, glutamate excitotoxicity, and neuroinflammation models; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse events and safety signals from animal studies; and a comparative assessment of five neuroprotective Polygala-derived saponins against PGSF on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1615Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Cogitum

    Acetylated amino acid derivative; synthetic N-acetylaspartate analog with neurometabolic and adaptogenic activity

    A potassium salt of N-acetyl-DL-aminosuccinic acid developed in France as an oral neurometabolic tonic for asthenic syndrome, cognitive fatigue, and pediatric neurodevelopmental delay, distinguished by its structural relationship to endogenous N-acetylaspartate and downstream modulation of glutamatergic and myelinogenic pathways.

    Abstract

    Cogitum is the proprietary pharmaceutical preparation of potassium N-acetyl-DL-aminosuccinate (bipotassium acetylaminosuccinate), a synthetic analog of N-acetylaspartate (NAA), the most concentrated free amino acid derivative in the mammalian central nervous system. The compound was developed in France and patented in the United States in 1969 (US 3,433,875) for the improvement of mental performance in adults experiencing intellectual overwork, memory disorders, and cognitive decline associated with senescence. The active substance provides an exogenous source of the acetylated aspartate moiety that participates in neuronal energy metabolism through the tricarboxylic acid cycle, serves as the obligate precursor for myelin lipid synthesis via oligodendrocytic aspartoacylase-mediated deacetylation, functions as an osmolyte maintaining neuronal volume homeostasis, and is the direct biosynthetic precursor of N-acetylaspartylglutamate (NAAG), the most abundant neuropeptide in the human brain and an endogenous agonist at the presynaptic metabotropic glutamate receptor type 3 (mGluR3). Cogitum is classified pharmacologically as a tonic agent and adaptogen; it is registered and marketed as a drinkable oral solution (250 mg per 10 mL ampoule) in France, Portugal, and several other jurisdictions, and is used extensively in Russian neuropediatric practice for the treatment of asthenic syndrome, attention deficit hyperactivity disorder with subclinical epileptiform activity, speech and language delay, and neurodevelopmental disorders in children aged seven years and older.

    The clinical evidence base includes a 2023 double-blind, randomized, placebo-controlled trial demonstrating that potassium N-acetylaminosuccinate at 750 mg daily for 21 days significantly reduced fatigue scores and improved complex cognitive functions in adults with asthenic syndrome compared to placebo, with no reported adverse events (Esin et al., 2023). Pediatric evidence comprises a 249-patient study in children with ADHD and subclinical epileptiform electroencephalographic activity demonstrating significant improvements in attention, memory, and speech without aggravation of epileptiform discharges or provocation of seizures; additional cohort studies in children with speech delay, traumatic brain injury sequelae, mental retardation, and schizotypal spectrum disorders have reported efficacy in improving cognitive and linguistic performance. The pharmacological rationale rests on the established neurobiology of endogenous N-acetylaspartate: NAA concentrations in the brain reach 10 millimolar or greater, are confined almost exclusively to neurons, and serve as the principal magnetic resonance spectroscopy marker of neuronal viability; reduced NAA is a consistent finding in neurodegenerative disease, traumatic brain injury, multiple sclerosis, and neurodevelopmental disorders. The exogenous provision of the acetylaminosuccinate moiety is hypothesized to support neuronal mitochondrial energy production, to provide acetate substrate for oligodendrocytic myelin lipid synthesis, and to augment NAAG-mediated glutamatergic neuromodulation.

    Safety data across pediatric and adult populations demonstrate excellent tolerability. The compound has no reported cases of overdose toxicity, produces no clinically significant drug interactions at registered doses, and is contraindicated only in cases of known hypersensitivity to the active substance or excipients. The principal limitation of the evidence base is the concentration of clinical research in Russian-language journals with limited replication in Western multicenter trial frameworks. This monograph documents the chemistry, synthesis, mechanism, pharmacokinetics, clinical evidence, sourcing, reconstitution, stack interactions, adverse events, and comparative assessment of Cogitum against five neurometabolic and nootropic alternatives on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1582Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • UBX1325

    Senolytic Bcl-xL inhibitor (phosphate prodrug); small-molecule inducer of apoptosis in senescent retinal vascular endothelial cells

    A first-in-class senolytic Bcl-xL inhibitor developed by Unity Biotechnology as an intravitreal therapy for diabetic macular edema and age-related macular degeneration, distinguished from conventional anti-VEGF agents by its mechanism of selective elimination of senescent retinal vascular cells and its potential for durable, disease-modifying efficacy from infrequent dosing.

    Abstract

    UBX1325 (foselutoclax) is a soluble phosphate prodrug that is cleaved rapidly in ocular tissues by ubiquitous phosphatases to yield the active parent molecule UBX0601, a potent inhibitor of the B-cell lymphoma-extra large (Bcl-xL) anti-apoptotic protein and related Bcl-2 family members. The compound was developed by Unity Biotechnology as the first senolytic therapeutic candidate designed for intravitreal administration in ophthalmologic indications, principally diabetic macular edema (DME), diabetic retinopathy (DR), and neovascular (wet) age-related macular degeneration (AMD). The senolytic mechanism is fundamentally distinct from the anti-vascular endothelial growth factor (anti-VEGF) agents that constitute the current standard of care for these conditions: rather than neutralizing a single cytokine to reduce vascular permeability, UBX1325 selectively induces apoptosis in senescent retinal vascular endothelial cells that have accumulated in areas of disease activity, thereby removing a persistent source of pro-inflammatory and pro-permeability signaling and potentially modifying the underlying disease process rather than managing its downstream consequences.

    The compound originated from a 2016 strategic licensing arrangement between Unity Biotechnology and Ascentage Pharma, under which Unity screened Ascentage’s Bcl-2 family compound library for candidates with senolytic activity against age-related disease targets. The selected molecule, BM-962, was optimized as a phosphate prodrug (UBX1325/foselutoclax) to improve aqueous solubility for ophthalmic formulation. Preclinical studies demonstrated that intravitreal administration of UBX1325 in oxygen-induced retinopathy and streptozotocin-induced diabetic retinopathy mouse models selectively eliminated senescent cells from diseased retinal vasculature while sparing healthy tissue, reduced retinal vascular permeability, and improved retinal function as measured by electroretinography. A Phase 1 single ascending dose study in 12 patients with advanced DME and wet AMD (NCT04537884) established safety and tolerability at doses up to 10 micrograms, with no dose-limiting toxicities, no treatment-related serious adverse events, and encouraging signals of visual acuity improvement and retinal thickness reduction persisting through 12 weeks. The Phase 2 BEHOLD trial (NCT04857996) enrolled 65 patients with DME who had suboptimal response to prior anti-VEGF therapy and randomized them to a single intravitreal injection of 10 micrograms UBX1325 or sham; at 48 weeks, UBX1325-treated patients gained a mean of 6.2 ETDRS letters from baseline (5.6 letters over sham), with 53 percent of treated patients requiring no anti-VEGF rescue through the full study duration compared to 22 percent in the sham arm. These results, published in Nature Medicine in 2024, represent the first clinical demonstration of senolytic therapy in ophthalmology. The Phase 2 ENVISION trial (NCT05275205) in wet AMD did not meet its primary non-inferiority endpoint versus aflibercept at 24 weeks, though 40 percent of UBX1325-treated patients required no anti-VEGF rescue through 48 weeks. The Phase 2b ASPIRE trial (NCT06011798) evaluated repeat dosing of UBX1325 every 8 weeks versus aflibercept every 8 weeks in 52 DME patients; at 36 weeks, UBX1325 produced mean gains of 5.5 ETDRS letters, achieving non-inferiority to aflibercept at most time points except the pre-specified primary endpoint (average of weeks 20 and 24), with superior performance in a pre-specified subgroup of patients with baseline central subfield thickness below 400 microns.

    This monograph reviews the chemistry, prodrug design, and molecular pharmacology of UBX1325; the senolytic mechanism of action through Bcl-xL inhibition; the preclinical pharmacology in retinal disease models; the complete clinical evidence base across Phase 1, BEHOLD, ENVISION, and ASPIRE trials; reconstitution and handling considerations for intravitreal formulation; stack interactions with anti-VEGF agents and corticosteroids; the adverse-event and safety profile; and a structured comparative assessment of five alternative approaches to DME therapy (aflibercept, faricimab, ranibizumab, navitoclax, and dasatinib plus quercetin) against UBX1325 on five competency standards. The compound is not approved by any regulatory authority as of the monograph revision date. Unity Biotechnology is advancing development toward registrational trials.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1600Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Cebranopadol

    Mixed nociceptin/orphanin FQ peptide (NOP) receptor and opioid receptor agonist analgesic

    A first-in-class spiro-indole analgesic with near-equipotent agonism at nociceptin/orphanin FQ peptide and classical opioid receptors, developed by Grunenthal and advanced by Tris Pharma through Phase 3 acute pain trials, distinguished from conventional opioids by NOP receptor-mediated attenuation of respiratory depression and abuse liability.

    Abstract

    Cebranopadol (GRT-6005, PRK-101, TRN-228) is a first-in-class small-molecule analgesic that acts as a high-affinity agonist at the nociceptin/orphanin FQ peptide (NOP) receptor and at the three classical opioid receptor subtypes (mu, kappa, and delta), with near-equipotent activation of the NOP and mu-opioid receptors at low-nanomolar concentrations. The compound was discovered at Grunenthal GmbH in Aachen, Germany, and first described in patent literature in 2002. Scientific characterization beginning in 2013 established cebranopadol as a spiro[cyclohexane-dihydropyrano[3,4-b]indole] derivative with binding affinities (Ki) of 0.7 nM at the human mu-opioid receptor, 0.9 nM at the human NOP receptor, 2.6 nM at the kappa-opioid receptor, and 18 nM at the delta-opioid receptor, and with functional potencies (EC50) of 1.2 nM (mu), 13 nM (NOP), 17 nM (kappa), and 110 nM (delta) in calcium mobilization assays, yielding a rank order of potency mu approximately equal to NOP, then kappa, then delta. The compound acts as a full agonist at the mu-opioid and delta-opioid receptors, a near-full agonist at the NOP receptor (89 percent relative efficacy), and a partial agonist at the kappa-opioid receptor (67 percent relative efficacy). A distinctive signaling feature is G-protein bias at the NOP receptor, where cebranopadol promotes G-protein coupling without measurable beta-arrestin 2 recruitment, while retaining full beta-arrestin 2 coupling at the mu-opioid receptor.

    The dual NOP and opioid receptor agonism produces a pharmacological profile that is differentiated from conventional mu-selective opioid analgesics in three respects: (1) enhanced relative potency in models of chronic neuropathic and inflammatory pain compared with acute nociceptive pain, with a seven-fold potency advantage in the mouse formalin test relative to the tail-withdrawal paradigm; (2) attenuation of opioid-type respiratory depression, with preclinical evidence of a ceiling effect on respiratory suppression attributable to the NOP receptor contribution; and (3) reduced abuse liability, demonstrated in a Phase 1 human abuse potential study showing less drug-liking and lower subjective effects relative to hydromorphone in non-dependent recreational opioid users, and in a separate study showing less abuse potential than tramadol and oxycodone. Additionally, preclinical studies demonstrated delayed analgesic tolerance development (26 days in cebranopadol-treated animals versus 11 days for morphine at equianalgesic doses in the chronic constriction injury model).

    Pharmacokinetics in humans are characterized by complete oral absorption with approximately 40 percent bioavailability reflecting first-pass hepatic metabolism, a late time to maximum plasma concentration (4 to 6 hours), a long terminal elimination half-life of 62 to 96 hours, and an operational half-life of approximately 24 hours supporting once-daily dosing. Steady-state plasma concentrations are achieved after approximately two weeks of daily administration, with an accumulation factor of approximately 2-fold and low peak-trough fluctuation (70 to 80 percent). Clearance is influenced by CYP2C9 phenotype, with poor and intermediate metabolizers showing reduced clearance relative to extensive metabolizers. The compound does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 at concentrations up to 250 nM, indicating a low potential for metabolic drug-drug interactions.

    Clinical development has encompassed more than 32 clinical trials involving more than 2,200 participants. A Phase 2 randomized, double-blind, placebo-controlled and active-controlled (tapentadol) trial in chronic low back pain (Christoph et al. 2017) demonstrated statistically significant and clinically relevant analgesic efficacy at doses of 200, 400, and 600 micrograms once daily over 14 weeks. A Phase 2a trial in postoperative acute pain demonstrated efficacy at 400 and 600 microgram doses. Two pivotal Phase 3 trials (ALLEVIATE-1, in post-abdominoplasty pain, and ALLEVIATE-2, in post-bunionectomy pain) met their primary efficacy endpoints, with cebranopadol 400 micrograms demonstrating significant reduction in pain intensity versus placebo. The ALLEVIATE-2 trial additionally showed that a higher proportion of cebranopadol-treated patients required no opioid rescue medication compared with placebo. Tris Pharma, which acquired worldwide rights to cebranopadol through its 2021 acquisition of Park Therapeutics, has announced plans for FDA submission. The compound is not yet approved by any regulatory authority and is not a scheduled controlled substance as of 2025. This monograph reviews the chemistry, synthesis, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, stack interactions, safety profile, and a comparative assessment of five analgesic candidates against cebranopadol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1597Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Halneuron

    Guanidinium alkaloid voltage-gated sodium channel blocker (tetrodotoxin formulation) for peripheral neuropathic and cancer-related pain

    A pharmaceutical-grade injectable formulation of tetrodotoxin developed by WEX Pharmaceuticals (now Dogwood Therapeutics) as a non-opioid, peripherally restricted analgesic that selectively blocks TTX-sensitive voltage-gated sodium channels on nociceptive neurons, with clinical development focused on chemotherapy-induced neuropathic pain and cancer-related pain.

    Abstract

    Halneuron is the proprietary injectable formulation of tetrodotoxin (TTX), a naturally occurring guanidinium alkaloid neurotoxin and potent, reversible blocker of TTX-sensitive voltage-gated sodium channels (VGSCs), developed by WEX Pharmaceuticals Inc. (Vancouver, British Columbia, Canada; now Dogwood Therapeutics Inc., NASDAQ: DWTX) as a non-opioid analgesic for moderate to severe neuropathic and cancer-related pain. The active pharmaceutical ingredient, tetrodotoxin (C11H17N3O8, molecular weight 319.3 g/mol, CAS 4368-28-9), blocks TTX-sensitive sodium channel subtypes NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.6, and NaV1.7 at low-nanomolar concentrations, with IC50 values ranging from approximately 2.3 nM (NaV1.6) to 36 nM (NaV1.7). The NaV1.7 subtype is of particular analgesic relevance: human loss-of-function mutations in SCN9A (the gene encoding NaV1.7) produce congenital insensitivity to pain, establishing the channel as a genetically validated analgesic target. Halneuron is administered by subcutaneous injection and does not cross the blood-brain barrier in pharmacologically significant quantities, conferring a safety profile that is free of the euphoria, sedation, tolerance, addiction, and cognitive impairment associated with opioid and centrally acting analgesics.

    The clinical development program has evaluated Halneuron in over 700 subjects across multiple Phase 1, Phase 2, and Phase 2b trials. The pivotal cancer pain trial (Hagen et al. 2017), a multicentre, randomized, double-blind, placebo-controlled study of 165 patients at 19 sites in Canada, Australia, and New Zealand, demonstrated a clinically significant estimated effect size of 16.2% on the pain endpoint for TTX 30 micrograms subcutaneously twice daily for four days versus placebo, with 51% of TTX-treated patients achieving 30% or greater pain reduction compared to 35% on placebo. An open-label safety and efficacy study (Hagen et al. 2011) in 77 cancer pain patients demonstrated that the analgesic effect persisted for weeks to months following a four-day treatment cycle, a finding that distinguishes TTX from conventional short-acting analgesics and suggests a disease-modifying or neuroplastic component to the mechanism. The Phase 2 dose-finding trial for chemotherapy-induced neuropathic pain (CINP; Bhatt et al. 2021) in 125 patients identified the 30 microgram twice-daily regimen as the optimal dose for further study, with cumulative responder analysis showing significant separation from placebo. The ongoing Phase 2b HALT-CINP trial, conducted at approximately 30 sites in the United States under Dogwood Therapeutics, reported positive interim results in December 2025 from 97 patients, with Halneuron-treated patients demonstrating separation from placebo on pain improvement over four weeks, a dropout rate of approximately 4.4% (substantially below rates observed with approved chronic pain agents), and encouraging safety and tolerability.

    Pharmacokinetics following subcutaneous injection are characterized by rapid absorption (time to maximum plasma concentration approximately 1.5 hours), dose-proportional exposure, and an elimination half-life of approximately 4.5 hours, with plasma concentrations falling below the limit of quantification within 24 hours. The compound is not metabolized by cytochrome P450 enzymes and does not produce the pharmacogenomic variability that complicates agents dependent on CYP2D6 or CYP3A4. Safety data from Phase 1 dose-escalation studies in healthy adults (doses of 15 to 45 micrograms subcutaneously) demonstrate that Halneuron is well tolerated, produces no QT prolongation, and carries no proarrhythmic proclivity. The most common adverse events across clinical trials are perioral paresthesia, oral numbness, headache, dizziness, nausea, and myalgia, all generally mild to moderate and self-limiting.

    This monograph reviews the chemistry, natural history, and pharmaceutical development of tetrodotoxin as Halneuron; the molecular pharmacology of TTX-sensitive sodium channel blockade with emphasis on NaV1.7; the human pharmacokinetic record; the preclinical analgesic evidence base in rodent models of neuropathic, inflammatory, and cancer pain; the complete clinical evidence base across cancer pain, chemotherapy-induced neuropathic pain, and ongoing Phase 2b trials; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five alternative analgesic candidates for chemotherapy-induced neuropathic pain (duloxetine, pregabalin, vixotrigine, capsaicin 8% patch, and lidocaine 5% patch) against Halneuron on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1577Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Vatiquinone

    Para-benzoquinone anti-ferroptotic agent and 15-lipoxygenase inhibitor derived from alpha-tocotrienol

    A synthetic alpha-tocotrienol quinone developed by Edison Pharmaceuticals as a first-in-class 15-lipoxygenase inhibitor and anti-ferroptotic cytoprotectant for inherited mitochondrial diseases and Friedreich ataxia, distinguished from earlier quinone antioxidants by nanomolar potency in oxidative stress models, NQO1-dependent intracellular bioactivation, and disease-modifying clinical signals in pediatric neurodegeneration.

    Abstract

    Vatiquinone (EPI-743, PTC-743, alpha-tocotrienol quinone) is a synthetic para-benzoquinone structurally derived from the vitamin E tocotrienol family and developed as an orally bioavailable, brain-penetrant cytoprotectant for inherited mitochondrial diseases and Friedreich ataxia. The compound is the oxidized (quinone) form of alpha-tocotrienol, bearing a 2,3,5-trimethyl-1,4-benzoquinone headgroup conjugated through a hydroxylated isoprenoid side chain. Vatiquinone is reduced intracellularly by NAD(P)H:quinone oxidoreductase 1 (NQO1) to its hydroquinone form, which functions as a potent inhibitor of 15-lipoxygenase (15-LO), the rate-limiting enzyme in the ferroptotic cell death cascade that drives lipid peroxidation in mitochondrially compromised neurons and other cell types. This dual mechanism (NQO1-dependent bioactivation followed by 15-LO inhibition) distinguishes vatiquinone from earlier quinone antioxidants such as coenzyme Q10 and idebenone and underwrites a 1,000- to 10,000-fold potency advantage in patient-derived fibroblast assays modeling the oxidative stress of mitochondrial disease.

    The compound was discovered at Edison Pharmaceuticals in the late 2000s, received Orphan Drug Designation from the United States Food and Drug Administration for Leigh syndrome and subsequently for Friedreich ataxia, and advanced through open-label Phase 2 studies in Leigh syndrome, Leber hereditary optic neuropathy, and other genetically defined mitochondrial disorders before the program was acquired by PTC Therapeutics in 2019. PTC Therapeutics conducted the registrational MOVE-FA Phase 3 trial (NCT04577352) in 143 patients with Friedreich ataxia aged 7 years and older. The primary endpoint of change from baseline in modified Friedreich Ataxia Rating Scale (mFARS) total score at 72 weeks did not reach statistical significance in the modified intent-to-treat population (treatment difference -1.61 points, p = 0.144). However, a prespecified sensitivity analysis of patients completing the full 72-week course demonstrated a 75 percent slowing of disease progression relative to placebo; the Upright Stability subscale of the mFARS showed a nominally significant treatment effect (-1.26 points, p = 0.021); and the Modified Fatigue Impact Scale showed a nominally significant benefit (-5.05 points, p = 0.025). In the long-term extension study, vatiquinone-treated patients progressed 3.75 points on the mFARS over 36 months compared to 7.48 points in a matched natural history cohort from the Friedreich Ataxia Clinical Outcome Measures Study registry, representing a clinically meaningful 50 percent slowing of disease progression. The FDA accepted the New Drug Application with Priority Review and set a Prescription Drug User Fee Act target date of August 19, 2025, but subsequently issued a Complete Response Letter concluding that the available data did not provide substantial evidence of efficacy and stipulating that an additional adequate and well-controlled clinical trial would be required for resubmission.

    Pharmacokinetics are characterized by high lipophilicity, a pronounced food effect (medium-fat meal increases systemic exposure up to 25-fold relative to fasting), CYP3A4-mediated hepatic metabolism, high plasma protein binding (greater than 96 percent), an effective half-life of approximately 9 hours supporting three-times-daily dosing with meals, and predominantly fecal elimination. The compound is generally well tolerated; the principal adverse events in clinical trials have been mild gastrointestinal symptoms and elevations in plasma cholesterol. This monograph reviews the chemistry, synthesis, and structural pharmacology of vatiquinone; the NQO1-mediated bioactivation and 15-lipoxygenase inhibition mechanism; the comprehensive pharmacokinetic record including drug-drug interaction characterization; the preclinical evidence across ferroptosis, mitochondrial disease, and Friedreich ataxia models; the clinical evidence base from Leigh syndrome through MOVE-FA; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative compounds (omaveloxolone, idebenone, coenzyme Q10, elamipretide, nicotinamide riboside) against vatiquinone on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1605Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Ezetimibe

    Selective cholesterol absorption inhibitor targeting Niemann-Pick C1-Like 1 (NPC1L1) transporter protein

    A 2-azetidinone cholesterol absorption inhibitor developed at the Schering-Plough Research Institute, first-in-class for selective blockade of Niemann-Pick C1-Like 1 mediated intestinal sterol uptake, with landmark cardiovascular outcomes evidence from the IMPROVE-IT trial and broad clinical positioning as add-on therapy to statins.

    Abstract

    Ezetimibe is a selective cholesterol absorption inhibitor and the founding member of a pharmacological class that targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein at the brush border membrane of small intestinal enterocytes and on the canalicular membrane of hepatocytes. Developed at the Schering-Plough Research Institute through a medicinal chemistry program that originated in acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor optimization, the compound was identified as SCH 58235 and advanced to regulatory approval by the United States Food and Drug Administration in October 2002 for the treatment of primary hypercholesterolemia, homozygous familial hypercholesterolemia, homozygous sitosterolemia, and mixed hyperlipidemia. At the standard oral dose of 10 mg once daily, ezetimibe reduces intestinal cholesterol absorption by approximately 54 percent, produces a 15 to 22 percent reduction in low-density lipoprotein cholesterol (LDL-C) as monotherapy, and provides an incremental 23 to 24 percent LDL-C reduction when added to ongoing statin therapy. The molecular mechanism involves direct binding to NPC1L1, a polytopic transmembrane protein with sterol-sensing domains homologous to the Niemann-Pick type C1 protein (NPC1), blocking the clathrin/AP2-mediated endocytosis of the NPC1L1-cholesterol complex and thereby preventing cholesterol translocation from the intestinal lumen into the enterocyte cytoplasm.

    The pharmacokinetic profile is dominated by rapid absorption followed by extensive first-pass glucuronidation to the pharmacologically active ezetimibe-glucuronide conjugate, which constitutes 80 to 90 percent of circulating drug. Both ezetimibe and its glucuronide undergo enterohepatic recirculation, producing a prolonged effective half-life of approximately 22 hours that supports once-daily dosing. Metabolism is mediated principally by uridine 5′-diphosphate-glucuronosyltransferase (UGT) isoenzymes 1A1, 1A3, and 2B15, with minimal cytochrome P450 involvement, conferring a favorable drug-drug interaction profile relative to the statin class. Approximately 78 percent of the administered dose is excreted in feces, predominantly as parent ezetimibe, with the remainder recovered in urine as the glucuronide conjugate.

    The clinical evidence base for ezetimibe is anchored by two landmark cardiovascular outcomes trials. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), published in 2015, randomized 18,144 patients with recent acute coronary syndrome to simvastatin plus ezetimibe versus simvastatin plus placebo and demonstrated a statistically significant 6.4 percent relative reduction in the primary composite cardiovascular endpoint (hazard ratio 0.936, p = 0.016) at a median follow-up of six years, establishing ezetimibe as the first non-statin lipid-lowering agent to demonstrate incremental cardiovascular benefit when added to statin therapy [1]. The SHARP trial (Study of Heart and Renal Protection) randomized approximately 9,270 patients with chronic kidney disease to simvastatin plus ezetimibe versus placebo and demonstrated significant reduction in major atherosclerotic events [2]. These trials collectively validated the LDL-C hypothesis beyond the statin class and positioned ezetimibe as a standard component of guideline-directed lipid management.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of ezetimibe; the NPC1L1 transporter biology and molecular mechanism of action; the comprehensive human pharmacokinetic record; the preclinical efficacy data in atherosclerosis and hypercholesterolemia models; the clinical evidence base across cardiovascular outcomes, chronic kidney disease, and combination therapy; sourcing and quality verification considerations; reconstitution and handling; stack interactions with statins, fibrates, bile acid sequestrants, and PCSK9 inhibitors; adverse events and safety signal including hepatic and musculoskeletal considerations; and a comparative assessment of five alternative non-statin lipid-lowering agents (bempedoic acid, evolocumab, alirocumab, inclisiran, colesevelam) against ezetimibe on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1559Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Etifoxine

    Non-benzodiazepine benzoxazine anxiolytic with dual GABAA receptor positive allosteric modulation and TSPO-mediated neurosteroidogenesis

    A non-benzodiazepine benzoxazine derivative developed by Hoechst AG and marketed as Stresam, distinguished from classical benzodiazepine anxiolytics by a dual mechanism encompassing direct positive allosteric modulation of beta2/beta3-containing GABAA receptors and stimulation of endogenous neurosteroid biosynthesis through the 18 kDa translocator protein (TSPO), conferring anxiolytic, anticonvulsant, and neuroprotective activity without the sedation, amnesia, tolerance, and dependence liabilities of the benzodiazepine class.

    Abstract

    Etifoxine (6-chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine) is a non-benzodiazepine anxiolytic of the benzoxazine structural class, first synthesized by Hoechst AG in 1966 and introduced for clinical use in France in 1979 under the trade name Stresam. The compound is marketed in approximately 40 countries for the treatment of anxiety disorders, principally adjustment disorders with anxiety, but has not been approved by the United States Food and Drug Administration or by the European Medicines Agency for centralized marketing authorization across the European Union. Etifoxine is pharmacologically distinguished from both the benzodiazepine class and from other non-benzodiazepine anxiolytics (buspirone, hydroxyzine) by a dual mechanism of action at the GABAergic system. The first mechanism is direct positive allosteric modulation of the GABAA receptor through binding at the beta subunit, with preferential potentiation of receptors containing beta2 or beta3 subunits, at a site distinct from the benzodiazepine binding site located at the alpha/gamma interface. The second mechanism is binding to the 18 kDa translocator protein (TSPO, formerly the peripheral benzodiazepine receptor) on the outer mitochondrial membrane, which stimulates the translocation of cholesterol into the mitochondrial matrix and the subsequent biosynthesis of endogenous neurosteroids, principally pregnenolone, progesterone, 5-alpha-dihydroprogesterone, and allopregnanolone. Allopregnanolone is itself a potent positive allosteric modulator of the GABAA receptor at the neurosteroid binding site (distinct from both the benzodiazepine and the etifoxine direct binding sites), producing a convergent, temporally extended potentiation of GABAergic inhibitory neurotransmission. This dual mechanism produces anxiolytic efficacy comparable to benzodiazepines in clinical trials of adjustment disorder with anxiety, with significantly reduced incidence of sedation, psychomotor impairment, amnesia, rebound anxiety on withdrawal, and physical dependence. Pharmacokinetics are characterized by rapid oral absorption, high bioavailability (approximately 90 percent), hepatic metabolism to an active metabolite (diethyl-etifoxine) with a half-life of approximately 20 hours, and predominant renal excretion. The clinical evidence base includes multiple randomized controlled trials comparing etifoxine to lorazepam, alprazolam, and placebo in adjustment disorder with anxiety, with the AMETIS study (a three-arm trial versus lorazepam and placebo) producing a notable negative result in which neither active arm separated from placebo. The compound has an established clinical safety profile over more than 40 years of marketed use, with rare but serious adverse events including severe cutaneous reactions (drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, erythema multiforme) and hepatotoxicity (acute cytolytic hepatitis), which prompted a 2021 European Medicines Agency Article 31 referral concluded in January 2022 with continued marketing authorization subject to contraindication in patients with prior severe dermatological or hepatic reactions. Beyond the anxiolytic indication, etifoxine has generated a substantial preclinical research literature in neuroprotection following peripheral nerve injury, traumatic brain injury, experimental autoimmune encephalomyelitis (a model of multiple sclerosis), and neuropathic pain, with the neuroprotective activity attributed to TSPO-mediated neurosteroidogenesis and downstream anti-inflammatory and neurotrophic effects. A deuterated analog, GRX-917 (GABA Therapeutics, a subsidiary of atai Life Sciences), has completed Phase 1 clinical trials with improved pharmacokinetic properties and is in development for anxiety and related disorders. This monograph reviews the chemistry, synthesis, and structural classification of etifoxine; the dual-receptor mechanism in molecular and electrophysiological detail; the comprehensive pharmacokinetic record; the preclinical pharmacology across neuroprotection, nerve injury, traumatic brain injury, and pain models; the clinical evidence base in anxiety disorders; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal including the EMA referral outcome; and a comparative assessment of five anxiolytic alternatives against etifoxine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1585Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Esmethadone

    Uncompetitive N-methyl-D-aspartate receptor antagonist with residual low-affinity opioid receptor activity

    The (S)-enantiomer of racemic methadone, developed by Relmada Therapeutics as REL-1017 for major depressive disorder on the basis of low-potency, voltage-dependent uncompetitive NMDA receptor channel blockade with preferential tonic inhibition of GluN2D-containing receptors, negligible clinically relevant opioid agonist activity, and rapid mTORC1- and BDNF-dependent antidepressant-like effects in preclinical models.

    Abstract

    Esmethadone (REL-1017, d-methadone, dextromethadone) is the (S)-enantiomer of the synthetic opioid methadone and a low-potency, voltage-dependent, uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor that was advanced through Phase 3 clinical development by Relmada Therapeutics for the adjunctive and monotherapy treatment of major depressive disorder (MDD). Unlike the (R)-enantiomer levomethadone, which carries the analgesic opioid activity of the racemate, esmethadone exhibits approximately 10-fold lower affinity at mu-opioid receptors and lacks clinically meaningful opioid agonist effects, respiratory depression, reinforcing properties, or physical dependence liability at the doses studied for antidepressant activity. The compound blocks NMDA receptor ion channels with IC50 values in the low micromolar range (approximately 13 to 68 micromolar across GluN2A through GluN2D subunit combinations), with functional selectivity for tonically active GluN2D-containing receptors under physiological magnesium concentrations. This tonic blockade is proposed to disinhibit downstream alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated glutamatergic transmission, activate mammalian target of rapamycin complex 1 (mTORC1) signaling, and increase brain-derived neurotrophic factor (BDNF) expression, producing rapid-onset antidepressant effects comparable in mechanism (though not in potency or dissociative liability) to ketamine and esketamine. Preclinical studies in rodent models of depressive-like behavior (forced swimming test, novelty-suppressed feeding test, female urine sniffing test, chronic unpredictable stress) demonstrated that oral esmethadone produced antidepressant effects comparable to injectable ketamine in magnitude and duration, mediated by mTORC1 signaling in the medial prefrontal cortex and blocked by the selective mTORC1 inhibitor rapamycin. A Phase 1 study in healthy volunteers demonstrated that esmethadone increased circulating BDNF levels, providing translational biomarker support for the preclinical mechanism. Pharmacokinetics are characterized by approximately 70 to 80 percent oral bioavailability, a long elimination half-life exceeding 30 hours that supports once-daily dosing, and hepatic metabolism principally through CYP3A4/5 and CYP2B6 to the inactive metabolite EDDP, with approximately half the dose recovered in urine and 40 percent in feces. The compound is a CYP2D6 inhibitor in vitro, producing clinically relevant increases in exposure of CYP2D6 substrates such as dextromethorphan. The Phase 2a randomized, double-blind, placebo-controlled adjunctive trial in MDD patients with inadequate response to standard antidepressants (Fava et al., American Journal of Psychiatry, 2022) demonstrated rapid and sustained improvement on the Montgomery-Asberg Depression Rating Scale (MADRS) at 25 mg and 50 mg daily doses, with effect sizes of 0.7 to 1.0 and day-14 remission rates of 31 percent and 39 percent versus 5 percent on placebo. No dissociative or psychotomimetic effects were observed. The Phase 3 Reliance I trial (published 2024) did not meet its primary efficacy endpoint, attributed in part to an elevated placebo response during the COVID-19 pandemic enrollment period. A second Phase 3 trial (Reliance II) was initiated, but interim analysis in late 2024 indicated that the study was unlikely to meet its primary efficacy endpoint, and Relmada Therapeutics paused further development of REL-1017. A 12-month open-label extension study in 624 MDD patients confirmed long-term safety and tolerability, with the most common treatment-related adverse events being headache (4.6 percent), nausea (4.2 percent), and dizziness (2.6 percent), no signal for cardiovascular, metabolic, neurological, or sexual adverse events, no suicides or suicide attempts, and no withdrawal syndrome on discontinuation. A dedicated abuse-potential study in recreational drug users demonstrated no meaningful abuse potential. The compound is not approved by any regulatory authority. This monograph reviews the chemistry, stereochemistry, and synthesis of esmethadone; the NMDA receptor pharmacology including subunit selectivity and downstream signaling; the opioid receptor binding profile; comprehensive pharmacokinetics including drug-drug interactions; the preclinical and clinical evidence base across Phase 1, Phase 2, and Phase 3 programs; sourcing and quality considerations; reconstitution and handling; stack interactions; the adverse-event and safety profile; and a comparative assessment of five alternative NMDA receptor-targeting antidepressant candidates against esmethadone on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1586Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Bacoside A

    Dammarane-type triterpenoid saponin mixture with multi-target nootropic, antioxidant, and neuroprotective activity

    A mixture of dammarane-type triterpenoid saponin glycosides isolated from Bacopa monnieri (Linn.) Wettst., constituting the principal bioactive fraction responsible for the cognitive-enhancing, neuroprotective, and antioxidant pharmacology of the Ayurvedic nootropic brahmi, with demonstrated activity across cholinergic modulation, serotonergic and dopaminergic neurotransmission, amyloid-beta aggregation inhibition, and synaptic plasticity.

    Abstract

    Bacoside A is a mixture of four dammarane-type triterpenoid saponin glycosides (bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X) isolated from the aerial parts and roots of Bacopa monnieri (Linn.) Wettst. (family Plantaginaceae, formerly Scrophulariaceae), a creeping perennial herb used in the Ayurvedic medical tradition for over three millennia under the name brahmi as a medhya rasayana (intellect-rejuvenating) agent. The bacoside A fraction, typically comprising 40 to 55 percent of standardized Bacopa monnieri extracts by weight, is the principal pharmacologically active constituent and the basis of standardization for all clinically studied Bacopa preparations including CDRI-08 (KeenMind, Synapsa), BacoMind, and BaCognize. The aglycone cores of the constituent saponins are jujubogenin and pseudojujubogenin, linked to arabinose-glucose trisaccharide chains that modulate solubility, bioavailability, and receptor interaction profiles.

    The pharmacology of bacoside A is multi-target and operates through at least five characterized mechanisms: (1) enhancement of cholinergic neurotransmission through upregulation of choline acetyltransferase activity and inhibition of acetylcholinesterase; (2) modulation of serotonergic neurotransmission through interaction with 5-HT1A and 5-HT2C receptor subtypes, with downstream effects on anxiety, mood, and cognitive flexibility; (3) dopaminergic modulation in prefrontal and hippocampal circuits; (4) potent antioxidant neuroprotection through scavenging of reactive oxygen species, suppression of lipid peroxidation, and upregulation of endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase; and (5) inhibition of amyloid-beta peptide fibrillation and cytotoxicity through direct interaction with amyloid-beta (1-42), reducing aggregation and membrane disruption in neuronal cell models. Additional mechanisms include enhancement of brain-derived neurotrophic factor (BDNF) expression, promotion of hippocampal dendritic branching and synaptic density in the CA1 and CA3 regions, and modulation of GABAergic neurotransmission.

    The clinical evidence base for Bacopa monnieri standardized to bacoside A content comprises at least nine randomized, double-blind, placebo-controlled trials in healthy adults, elderly populations, and children, conducted principally at Swinburne University of Technology (Stough laboratory), the University of Wollongong (Roodenrys laboratory), and multiple Indian academic medical centers. The consistent finding across these trials is statistically significant improvement in speed of visual information processing, learning rate, memory consolidation, and delayed recall after 8 to 12 weeks of oral administration at 300 to 450 mg per day of extract standardized to 50 to 55 percent bacosides, with secondary anxiolytic effects and reduction in state anxiety scores. Effect onset requires sustained administration; acute single-dose cognitive enhancement has not been reliably demonstrated. A 2012 systematic review by Pase et al. confirmed the cognitive-enhancing effects across six qualifying trials and identified memory consolidation as the most reproducible endpoint.

    Pharmacokinetic characterization of isolated bacoside A in humans remains incomplete. In silico ADMET analyses of the constituent saponins and their aglycone derivatives indicate favorable predicted oral absorption for the aglycones (jujubogenin, pseudojujubogenin), with central nervous system drug-like properties including adequate predicted blood-brain barrier penetration. The intact glycosides are poorly water-soluble and are believed to undergo gastrointestinal hydrolysis to active aglycone metabolites, a transformation consistent with the delayed onset of clinical effect observed in human trials. Hepatic metabolism involves cytochrome P450 enzymes; Bacopa monnieri standardized extract has been demonstrated to inhibit CYP3A4, CYP2C9, CYP2C19, and CYP1A2 in vitro at estimated gut concentrations, with potential for clinically significant herb-drug interactions.

    The compound is well tolerated at standard doses (300 to 600 mg per day of standardized extract). The principal adverse events are mild gastrointestinal disturbances (nausea, abdominal cramps, increased stool frequency) that typically attenuate with continued use. No hepatotoxicity has been reported despite widespread use. A thyroid-stimulating effect (elevation of serum T4) has been characterized in animal studies and warrants caution in individuals with thyroid disorders. This monograph reviews the chemistry, biosynthesis, and structural characterization of bacoside A; the multi-target molecular pharmacology; the pharmacokinetic profile; the preclinical neuroprotective and cognitive evidence; the clinical trial evidence base; sourcing and quality verification for standardized extracts; reconstitution and handling; stack interactions; adverse events and safety; and a comparative assessment of five alternative nootropic candidates (Hericium erinaceus, Ginkgo biloba EGb 761, phosphatidylserine, alpha-GPC, and citicoline) against bacoside A on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1614Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.